FDA 483 - Prodose, Inc. - January 25, 2017
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Spirit Pharmaceuticals, a pharmaceutical packager and distributor in Ronkonkoma, NY, revealed significant deficiencies in its quality control unit and equipment maintenance. Observations included failures in packaging line qualification, inadequate investigation of product complaints regarding cloudiness/crystallization, and incomplete employee training records. Additionally, the firm's routine checking of metal detectors on packaging lines was found to be deficient, lacking non-ferrous metal challenges.
ID · 5adb229d-22fc-4b27-93d4-3081efef8e2c